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Abstract
Background: While there is an increasing emphasis on patient empowerment and shared decision-
making, subjective values for attributes associated with their treatment still need to be measured and
considered. This contribution seeks to define properties of an ideal drug treatment of individuals
concerned with Attention-Deficit/Hyperactivity Disorder (ADHD). Because of the lack of information on
patient needs in the decision-makers assessment of health services, the individuals' preferences often play
a subordinate role at present. Discrete Choice Experiments offer strategies for eliciting subjective values
and making them accessible for physicians and other health care professionals.
Methods: The evidence comes from a Discrete Choice Experiments (DCE) performed in 2007. After
reviewing the literature about preferences of ADHS we conducted a qualitative study with four focus
groups consisting of five to eleven ADHS-patients each. In order to achieve content validity, we aimed at
collecting all relevant factors for an ideal ADHS treatment. In a subsequent quantitative study phase (n =
219), data was collected in an online or paper-pencil self-completed questionnaire. It included
sociodemographic data, health status and patients' preferences of therapy characteristics using direct
measurement (23 items on a five-point Likert-scale) as well as a Discrete-Choice-Experiment (DCE, six
factors in a fold-over design).
Results: Those concerned were capable of clearly defining success criteria and expectations. In the direct
assessment and the DCE, respondents attached special significance to the improvement of their social
situation and emotional state (relative importance 40%). Another essential factor was the desire for drugs
with a long-lasting effect over the day (relative importance 18%). Other criteria, such as flexibility and
discretion, were less important to the respondents (6% and 9%, respectively).
Conclusion: Results point out that ADHD patients and their family members have clear ideas of their
needs. This is especially important against the backdrop of present discussions in the healthcare sector on
the relevance of patient reported outcomes (PROs) and shared decision-making. The combination of the
methods used in this study offer promising strategies to elicit subjective values and making them accessible
for health care professionals in a manner that drives health choices.
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Background
This contribution seeks to measure needs and expecta-
tions of individuals concerned with Attention-Deficit/
Hyperactivity Disorder (ADHD). Every approach to treat-
ment is centred on the patient. It is therefore necessary to
take adequate account of the patients' needs and values
when providing and assessing treatments or technologies
used in therapy. However, the assessment of health care
professionals of the effects of illness and treatment on the
patients' quality of life may differ from the way the patient
feels about these. Differences between clinical findings
which are usually more or less objective  and the subjec-
tive experience of the patient give rise to many questions.
Treatment is concerned not only with changing clinical
symptoms, but furthermore with ensuring that patients
themselves experience an improvement in their health
state. When the efficacy of different treatments is viewed
from the patients' perspective in this way, two "objec-
tively" equal effective approaches to treatment can often
be seen in very different lights. Moreover, it can be
assumed that greater benefit from the patients' point of
view will have a positive effect on compliance and also
fundamentally strengthen the relationship between the
patient and therapist. While it was shown in several open
label studies, that drug treatment can improve the quality
of life of ADHD patients and their families [1,2], it
remains unknown which treatment aspects are perceived
as most important.
At present, however, the assessment of medicinal prod-
ucts by physicians and other decision-makers is primarily
based on the results of studies on clinical efficacy and
safety. The patients' perspective and the needs and values
of those concerned remain largely unknown and conse-
quently play a rather subordinate role [3]. This is mainly
due to the lack of adequate studies, as is the case with drug
treatment in attention-deficit hyperactivity disorder
(ADHD).
With a worldwide prevalence of 1  7%, ADHD is one of
the most common psychiatric disorders in children and
adolescents [4]. The core symptoms of ADHD consist in
abnormal impulsive behaviour, a deficit in attention, and
hyperactivity. They are relevant not only because of their
prevalence, but also because of their consequences in the
short, medium and long term, which far exceed the imme-
diate concerns of the healthcare system [5]. In addition to
family stress and problems, disturbed social behaviour,
problems at school and at work and the attendant
impaired quality of life, numerous significant long-term
pathological developmental defects are known [6,7].
This condition is usually treated by using a multimodal
therapeutic concept, consisting of a combination or series
of different approaches to treatment that should be tai-
lored to the individual needs of the patient. Standard
approaches include psychosocial and behavioural, as well
as psychopharmacological therapies [8]. Different drug
treatments, in different pharmaceutical forms and with
different therapeutic time frames, are available for
patients. In Germany, the most frequently used drug is
methylphenidate (MPH) [9]. The individual short- and
long-acting MPH products have different effect profiles,
which can be used to suit the individual everyday life, and
thus have an additional effect on the quality of life of
patients and their families [10].
The objective of this study is to define properties of an
ideal ADHD drug treatment from the patient and parents'
perspective. In addition to "classic" medical outcomes,
other aspects important to the patient, e.g. quality of life
and social behaviour, were included. A Discrete Choice
Experiments (DCE) was performed in 2007 as a method
to elicit preferences and making them accessible for phy-
sicians and other health care professionals.
Methods
The study was divided into two parts: a qualitative part to
collect relevant attributes and a quantitative main study to
elicit the patients' preferences. The qualitative pre-investi-
gation determined the desires and expectations of patients
and their relatives with regard to the drug treatment of
ADHD. In the principal investigation phase, these were
then used as a basis for assessing the previously defined
pools of characteristics with regard to their individual
degree of relevance. The study is a social science survey. It
does not contain personal data (completely anonymous
survey), surgeries (tests, experiments, medication), bio-
medical research or additional data, like in many epide-
miological investigations. Therefore an ethic vote was not
necessary. Study goals were explained to all participants
and all gave written informed consent for their participa-
tion. (Figure 1)
Qualitative study
Prior to the main study, we performed a qualitative study
to identify important aspects of an ideal ADHS treatment
(summer 2007). Patient advocacy groups „ADHS Selb-
sthilfe e. V.“ asked patients to participate. They were inter-
viewed in four focus groups (5  11 parents of patients).
The aim was to ensure content validity, i.e. the accuracy of
these characteristics. On the basis of literature research
and the results of these focus groups 23 aspects were
selected for the main study. In a pretest, the questionnaire
was tested for comprehensibility by parents of patients
and adolescent patients (n = 14). Based on the results of
the pretest we finalised the questionnaire.BMC Health Services Research 2009, 9:149 http://www.biomedcentral.com/1472-6963/9/149
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Study design of the Discrete Choice Experiment Figure 1
Study design of the Discrete Choice Experiment.
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Main study
The main study was performed as an anonymous survey,
which started in early November 2007, using either online
or paper questionnaires. Family members (mostly par-
ents) and patients (>14 years) were contacted either in
writing and distributing the paper-based questionnaire
version with stamped addressed envelopes, or via email/
internet. Patient advocacy groups helped in distributing
paper-based questionnaires and the link to the online ver-
sion. No personal data such as addresses, names or phone
numbers were collected.
The questionnaire encompassed three main domains:
￿ Part A: Sociodemographic characteristics: e.g. age,
gender, educational level, previous therapy, and mem-
ber of patient advocacy group.
￿ Part B: Current health status (Health related Quality
of Life (HRQoL), SF12v2, German version of the
SOEP, SozioOekonomisches Panel), several questions
concerning utilization of medical services.
￿ Part C: Assessment of importance of ADHS-therapy
characteristics. Both methods are based on a multiat-
tributive method to analyse preferences and assess
combinations of characteristics.
￿ C1: Direct assessment of importance of 23 items
derived from the qualitative pre-investigation. The
importance of these criteria had to be assessed on
a five-point Likert scale. For this direct measure-
ment of preferences, respondents were directly
asked for their subjective assessment of individual
characteristics and dimensions.
￿ C2: Discrete Choice Experiment (DCE) used in
this study included 6 factors: duration of effect,
side effects, dosage, discretion, emotional state
and social situation. For each of these factors, 2
exactly opposite (dichotomous) dimensions were
given. In a fold-over design, 8 pairs of therapies
were presented, each with 2 fictitious drugs (alter-
natives A and B). The contrary properties of the
drugs were assigned at random. (Table 1)
Discrete Choice Experiment (DCE)
McFadden's work on discrete choice models [11] intro-
duced feasible techniques for estimating a complete char-
acteristics-based discrete choice model of demand.
Attention to preferences as an input into health care deci-
sion-making is rooted in the application of decision the-
ory to the understanding of personal choice [12]. The
premise of the DCE is that rational individuals will always
choose the alternative with the higher level of expected
utility.
Discrete choice models have recently gained importance
in the study of innovative health technologies and of non-
market goods in the health care sector [13-15]. A key fea-
ture of these models is the specification of utilities associ-
ated with the alternatives in terms of choice characteristics
and individual preferences [16].
Discrete Choice Experiments offer strategies for eliciting
preferences to value health and health care [13]. The term
patient preferences still lacks a consistent definition;
despite these differences in definition, there appears to be
convergence in the view that patient preferences are state-
ments made by individuals regarding their needs, values
and expectations and the relative importance of treatment
properties. Therefore these preferences refer to the indi-
vidual evaluation of dimensions of health outcomes. For
Table 1: Example of a therapy pair
Pair 1 Properties of treatment/therapy/Drug AP r o p e r t i e s  o f  t r e a tment/therapy/Drug B
Duration of effect Long (all day) Short (half day)
Side effects Loss of weight occurs None
Dosage/dosage form Always the same Variable, combinable
Discretion Intake of drug obvious Intake of drug not obvious
Emotional state Mood swings may occur No mood swings
Social situation No problems with friends, hobbies Problems with friends, hobbies
Please tick:  I would choose A  I would choose B
In the original DCE no colours were used to indicate positive and negative attribute levels.BMC Health Services Research 2009, 9:149 http://www.biomedcentral.com/1472-6963/9/149
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measuring preferences in the healthcare sector, respond-
ents are presented with 2 alternative (fictitious) health
services/treatments, which combine different contrary
product properties. The respondents have to select the
alternatives in accordance with their individual prefer-
ences. The decision is based on a comparison of utility lev-
els attained.
DCEs are limited to the use of only a few characteristics. It
is very important to cover all the relevant fields when
selecting the items for the DCE. The DCE used in this
study included six dimensions: duration of effect, side
effects, dosage, discretion, emotional state and social situ-
ation. All the 6 characteristics chosen were of high impor-
tance in the direct measurement and in the qualitative
study. For each of these factors, two opposite (dichoto-
mous) poles were given, e.g. 'long' and 'short' for duration
of effect [17]. In a fold-over design, eight pairs of therapies
were presented (labelled as alternatives A and B). The
eight basic scenarios to be fold over were generated auto-
matically as an orthogonal design using the software
SPEED. The design demonstrated uncorrelated main
effects and an efficiency of 100% [18].
The evaluation of the DCE involved descriptive methods
(frequency tables, statistics of distribution), bivariate pro-
cedures (cross tables, comparisons of means, ANOVA),
and complex multivariate procedures (factor analysis
[PCA], probit models, logit models). The level of statisti-
cal significance in all analyses was p < 0.05 (2-sided).
Results
Patient Characteristics (Part A and B)
In November 2007, patients and parents completed the
questionnaires (n = 219) in the 4-week documentation
period. The vast majority of respondents were mothers of
ADHD patients (79%); fathers (9%) and adolescent
patients (6%). Most of the patients were male (83%), with
a broad spectrum of ages (mean = 15 years). The follow-
ing age groups were combined into one due to the small
numbers of cases: up to 7 years, 19  25 years, and >25
years.
The majority of patients had first been diagnosed with
ADHD at an age of 6  9 years; most were 6 years old
(range: 1  46 years; mean: 8.3 years). (Figure 2)
The first part of the questionnaire contained a total of 7
questions regarding the use of facilities available to par-
ents: two-thirds (67%) of respondents belonged to a
patient advocacy group at the time of the survey, 18% had
previously been active in a patient advocacy group, and
15% had never belonged to such a group. A similar pic-
ture emerged for the use of psycho-educational facilities:
Age at time of first diagnosis Figure 2
Age at time of first diagnosis.
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70% were using such facilities in the period of the survey,
17% had done so previously, and 14% had never made
use of them. Much lower proportions had made use of
parental training or coaching. Only 26% made use of
parental training, and 22% preferred parental coaching.
The vast majority had no experience of the following edu-
cational opportunities: 5% made use of systematic family
therapy, 10% family assistance, and 8% therapeutic day
centres.
The health status of the child or adolescent concerned was
classed as "very good" or "good" by 53% of respondents,
"satisfactory" by 33%, "not so good" by 11%, and "bad"
by 5%. With regard to changes in health status over the
past 12 months, a marked improvement had been seen by
42%; 14% had noticed deterioration, and the remaining
44% had seen no change. (Figure 3)
The subjects were presented with a total of 10 treatment
schemes to be assessed; information on their past experi-
ence was also relevant in this context. The vast majority of
91% professed to have had experience with drug therapy,
and 76% were currently using it. About 50% had used
ergo therapy and behavioural therapy before, while only
10% and 18%, respectively, were using them at the time
of responding. About one-third (36%) had experience
with therapy for the treatment of co-morbid disturbances.
At the time of responding, 13% of subjects were still being
treated for such problems.
When asked about the current extent of their medication,
40% stated that they were using an "all-day drug treat-
ment", on all days of the week. 17% used medication on
school days, but less at weekends and in school holidays.
26% of respondents treated the disorder on a half-daily
basis; 18% of these discontinued their treatment on week-
ends or during school holidays. A total of 17% professed
to prefer non-drug methods. (Figure 4)
Relevance of therapy characteristics: Direct assessment 
(Part C1)
We conducted a direct assessment in order to analyse the
relevance of therapy characteristics. In part C1, respond-
ents had to rate the importance of 23 therapy characteris-
tics using a five-point Likert-Scale, ranging from "very
important" to "not important". For subsequent evalua-
tion, the ratings were transformed into a numerical range
from 0 ("not important") to 100 ("very important"). It
emerged that all but 2 of these items reached relatively
high scores, meaning that patients consider most of them
to be very important with regard to the quality of a ther-
apy approach. This is not surprising, since only aspects
were presented, that were rated as important according to
the literature and the qualitative study/focus groups.
Change in health status over the past 12 months Figure 3
Change in health status over the past 12 months.
A6.Change in health status over the past 12 months
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The greatest relevance (100 - 90) was attributed to
"improving the child's emotional state" (mean value =
94), "little or no addictive potential" (94), and "improved
ability to concentrate" (93). (Figure 5)
Response styles are a source of contamination in ques-
tionnaire ratings [19]. Regarding the rating scale
responses it should be stated that rating scales do not
incorporate the trade-offs inherent in real-life decision-
making. Therefore they threaten the validity of conclu-
sions drawn from such research data. In order to draw
valid conclusions we conducted a DCE.
Preferences in the Discrete-Choice-Experiment (Part C2)
The DCE was built up with eight pairs (choices) each con-
sisting of six dichotomous aspects. All the six characteris-
tics chosen were of high importance in the direct
measurement and in the qualitative study: duration of
effect, side effects, dosage, discretion, emotional state, and
social situation. To achieve maximum differentiation
between the two alternatives a fold-over design was used:
each of the eight pairs was presented to the subjects as
alternatives A and B, with A being the exact "mirror
image" of B.
This approach created varying decision options: some
choices were relatively simple because one alternative was
in almost all aspects apparently better than the other. On
the contrary, in difficult decisions the advantages and dis-
advantages were mostly equally distributed which made
the alternatives more equivalent and the choice more dif-
ficult.
From the patient's point of view, the 6 aspects presented
influenced the choice of the best therapy to different
degrees. The greatest importance was attributed to "ena-
bling social contacts" (Item 6; 3,162 coefficient). This was
followed by two items with almost the same degree of
importance: by "emotional state: no mood swings" (Item
5; 1,644 coefficient) and "duration of effect: long (all
day)" (Item 1; 1,437 coefficient). If one of these character-
istics was present, this treatment alternative was very likely
to be selected. These were followed at a considerable dis-
tance by "discretion" (Item 4; 0,727 coefficient), "dosage"
(Item 3; 0,468 coefficient), and "side effects" (Item 2;
0,470 coefficient). A supplementary (partial) log-likeli-
hood analysis as proposed by Lancsar et al. [15] yielded to
the same hierarchy as the interpretation based on the six
item-coefficients. All 6 aspects were statistically signifi-
cant, with a level of p < 0.001 for Items 1, 4, 5 and 6, and
p < 0.01 for Items 2 and 3. (Table 2)
At the end of the questionnaire, subjects were asked about
their degree of satisfaction with their present treatment. In
Medication used during the study period Figure 4
Medication used during the study period.
B4.Current medication
36; 17%
83; 40%
36; 17%
16; 8%
37; 18%
1; 0%
no current use of medication
a) all-day; on school days, weekends, and
school holidays
b) all-day on school days; less on weekends
and school holidays
c) half-day; on school days, weekends, and
school holidays
d) half-day on school days; less on weekends
and school holidays
e) other regimensBMC Health Services Research 2009, 9:149 http://www.biomedcentral.com/1472-6963/9/149
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total, 58% were "satisfied" or "very satisfied", while about
one-third chose the category "yes and no", and 11%
expressed a negative opinion of their present therapy.
Discussion
The objective of the present study was to elicit the prefer-
ences of patients and their parents with regard to the drug
treatment of ADHD. Based on a qualitative (pre) investi-
gation to ensure content validity, quantitative measure-
ments of preference were subsequently performed,
including a Discrete Choice Experiment (DCE).
By means of multiattributive preference measurements,
DCE designs can provide valid and robust results on rele-
vant outcomes of ADHD treatment from the patient's
point of view.
With a combination of direct questions  i.e. direct meas-
urements of importance  and a DCE, it is possible to sim-
ulate real-life decision-making situations for patients. The
combination of direct assessment of importance and DCE
is a valid combined survey technique for eliciting prefer-
ences of patients with ADHS. The former ensures content
validity (the possibility to measure a longer list of poten-
tially important aspects), the latter has the advantage to
combine positive and negative therapy characteristics and
to avoid the problem of ceiling effects and "all-is-impor-
tant" results.
There are a few limitations to this study that need to be
pointed out. First, for practicability DCE needs to be per-
formed with preferably the least number of parameter and
pairs. The level of complexity of our study turned out to
manageable for the participants. Second, there is the diffi-
culty that the questionnaire was widely spread (paper and
pencil version and online version). The number of
patients who got into contact with the questionnaire is
unknown  therefore, response rates cannot be calculated.
The intense usage of the paper version shows that offering
the paper copy is important and useful  at least in this
patient population. Third, the study participants are prob-
ably more committed and well informed than the average
of ADHS patient, because most of the respondents were
therapy-experienced and members of patient advocacy
groups. We do not know if this selection could have
potentially biased the preference assessments.
In spite of these limitations, however, two results stand
out. Against the backdrop of ADHD, multiattributive pro-
cedures allow an assessment of the benefit of therapy
from the point of view of patients and parents. Therefore,
from a methodological point of view, both approaches
Importance and preferences: direct questioning Figure 5
Importance and preferences: direct questioning.
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should always be used in parallel for preference studies, as
a direct measurement of importance makes it possible to
cover more aspects than can be elicited in combination by
the DCE. The results of the two methods  the direct and
indirect (DCE) method  are largely equivalent: as can be
seen from the results of this study, patients and parents
have clear ideas about their own needs, and are able to
assess different therapeutic approaches. Patients or their
parents attach particular importance to an improvement
of their social situation and emotional state. This means
that a balanced mood and a positive social environment
(friends and hobbies) contribute significantly to the over-
all patient benefit from a drug treatment. It can be con-
cluded that these treatment outcomes heavily influence
parents' or older patients' choice to administer a drug
treatment. A long duration of effect throughout the day is
considered almost as desirable as the improvement of the
emotional state, whereas other factors, such as discretion
and flexibility, appear to be less important to patients.
Conclusion
The patients' view and desires in healthcare decisions (e.g.
attributes of therapies) are often not sufficiently consid-
ered. The Institute of Medicine report in 2001, "Crossing
the Quality Chasm" [20] emphasizes that health decisions
should be customized based on patients' needs and val-
ues. However, in times of limited healthcare resources,
shared decision making as patients involvement in treat-
ment decisions have been encouraged in recent years. This
requires an understanding of patients' priorities concern-
ing treatment decision-making. These findings supply
important information on the benefit of therapy from the
patients' point of view, and should be increasingly taken
into account when deciding on therapeutic approaches.
They make an important contribution to the patient-ori-
ented optimization of treatments and can thus help to
improve the final outcome of treatment. If patient needs
are taken into account adequately, it should be safe to
assume that this will increase compliance, which is an
essential requirement. This study also supports the efforts
for increased consideration of patient benefit as a new
quality criterion in the assessment of drug treatments.
Especially where clear differentiation between treatments
in terms of medical and financial aspects is difficult, com-
prehensive information on patient benefits to be expected
can be very useful in the prioritization of treatment
approaches. Studies of this type can thus help to stimulate
new discussions in the healthcare sector, leading to the
formulation of increasingly patient-centred care concepts
in the long term.
Table 2: Results of the random effects model (DCE)
Item Characteristic and dimension Coefficient SE (coeff) Significance Partial log likelihood when item 
omitted
1 Duration of effect: long (all day) 1.437 0.169 *** -797.3
Duration of effect: short (half day) -1.437 0.169 ***
2 Side effects: none 0.470 0.147 ** -756.2
Side effects: loss of weight may occur -0.470 0.147 **
3 Dosage/dosage form: variable, combinable 0.468 0.155 ** -755.3
Fixed dosage and dosage form -0.468 0.155 **
4 Discretion: intake not obvious 0.727 0.143 *** -763.7
Discretion: intake obvious -0.727 0.143 ***
5 Emotional state: no mood swings 1.644 0.167 *** -813.6
Emotional state: mood swings may occur -1.644 0.167 ***
6 Social situation: no problems with friends, 
hobbies
3.162 0.169 *** -1055.1
Social situation: problems with friends, hobbies -3.162 0.169 ***
Model constant -4.144 0.294 ***
***: p < 0.001, **: p < 0.01, *: p < 0.05
Model parameters:
Wald Chi2 (df = 6) = 379.67
Log likelihood = -750.8
Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***)
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It would also be useful to conduct further studies that, in
addition to assessing the preferences of patients and par-
ents, will consider the choices and decisions of actual and
potential decision-makers in the healthcare sector. In this
case, the comparison of patient preferences and expert
opinions may reveal discrepant aspects of treatment that
need improvement. A resource-oriented, balanced
approach to treatment, which also serves the needs of the
individual patient, will not be possible unless full account
is taken of the patients' actual demands.
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